Persistence and reasons for discontinuation of therapy with IL-17 or TNF-ALPHA inhibitors in patients with psoriatic arthritis – Experience of a tertiary center

Skala Kavanagh, Hana; Ćavar, Stipe; Grubišić, Frane; Doko Vajdić, Ines; Kraljević, Jadranka; Glavaš, Dragan; Grazio, Simeon

doi:10.33004/reumatizam-supp-71-1-21

Reumatizam, Vol. 71 No. Supp 1, 2024.

Sažetak sa skupa

https://doi.org/10.33004/reumatizam-supp-71-1-21

Persistence and reasons for discontinuation of therapy with IL-17 or TNF-ALPHA inhibitors in patients with psoriatic arthritis – Experience of a tertiary center

Hana Skala Kavanagh orcid.org/0000-0002-9340-0809 *
Stipe Ćavar
Frane Grubišić
Ines Doko Vajdić
Jadranka Kraljević
Dragan Glavaš
Simeon Grazio

* Dopisni autor.

Puni tekst: hrvatski pdf 651 Kb

str. 23-24

preuzimanja: 44

citiraj

APA 6th Edition

Skala Kavanagh, H., Ćavar, S., Grubišić, F., Doko Vajdić, I., Kraljević, J., Glavaš, D. i Grazio, S. (2024). Persistence and reasons for discontinuation of therapy with IL-17 or TNF-ALPHA inhibitors in patients with psoriatic arthritis – Experience of a tertiary center. Reumatizam, 71 (Supp 1). https://doi.org/10.33004/reumatizam-supp-71-1-21

MLA 8th Edition

Skala Kavanagh, Hana, et al. "Persistence and reasons for discontinuation of therapy with IL-17 or TNF-ALPHA inhibitors in patients with psoriatic arthritis – Experience of a tertiary center." Reumatizam, vol. 71, br. Supp 1, 2024 https://doi.org/10.33004/reumatizam-supp-71-1-21. Citirano 29.12.2024.

Chicago 17th Edition

Skala Kavanagh, Hana, Stipe Ćavar, Frane Grubišić, Ines Doko Vajdić, Jadranka Kraljević, Dragan Glavaš i Simeon Grazio. "Persistence and reasons for discontinuation of therapy with IL-17 or TNF-ALPHA inhibitors in patients with psoriatic arthritis – Experience of a tertiary center." Reumatizam 71, br. Supp 1 https://doi.org/10.33004/reumatizam-supp-71-1-21

Harvard

Skala Kavanagh, H., et al. (2024). 'Persistence and reasons for discontinuation of therapy with IL-17 or TNF-ALPHA inhibitors in patients with psoriatic arthritis – Experience of a tertiary center', Reumatizam, 71(Supp 1). https://doi.org/10.33004/reumatizam-supp-71-1-21

Vancouver

Skala Kavanagh H, Ćavar S, Grubišić F, Doko Vajdić I, Kraljević J, Glavaš D i sur. Persistence and reasons for discontinuation of therapy with IL-17 or TNF-ALPHA inhibitors in patients with psoriatic arthritis – Experience of a tertiary center. Reumatizam [Internet]. 2024 [pristupljeno 29.12.2024.];71(Supp 1). https://doi.org/10.33004/reumatizam-supp-71-1-21

IEEE

H. Skala Kavanagh, et al., "Persistence and reasons for discontinuation of therapy with IL-17 or TNF-ALPHA inhibitors in patients with psoriatic arthritis – Experience of a tertiary center", Reumatizam, vol.71, br. Supp 1, 2024. [Online]. https://doi.org/10.33004/reumatizam-supp-71-1-21

Sažetak

Ključne riječi

Hrčak ID:

322090

URI

https://hrcak.srce.hr/322090

Datum izdavanja:

24.10.2024.

Podaci na drugim jezicima: hrvatski

Posjeta: 118 *

Prijava i registracija

Reumatizam, Vol. 71 No. Supp 1, 2024.

Sažetak

Ključne riječi

Hrčak ID:

URI

Datum izdavanja: